Literature DB >> 17154184

SK-NEP-1 and Rh1 are Ewing family tumor lines.

Malcolm A Smith1, Christopher L Morton, Doris Phelps, Kevin Girtman, Geoffrey Neale, Peter J Houghton.   

Abstract

The utility of preclinical models of childhood cancers is contingent upon reliably classifying them with their corresponding clinical counterparts. Molecular tools such as gene expression profiling allow researchers to confirm the similarity between clinical tumors and preclinical models. We describe the use of gene expression profiling to show that SK-NEP-1, a cell line previously thought to represent anaplastic Wilms tumor, is instead related to Ewing sarcoma. RT-PCR confirmed that SK-NEP-1 expresses EWS-FLI1 gene fusion transcripts characteristic of Ewing sarcoma, and DNA sequencing demonstrated the joining of exon 7 of EWS with exon 5 of FLI1 for these transcripts. Rh1, which was previously categorized as an alveolar rhabdomyosarcoma cell line, also has a gene expression profile suggestive of Ewing sarcoma and expresses EWS-FLI1 fusion transcripts in which exon 7 of EWS is joined with exon 6 of FLI1. These examples illustrate the importance of molecularly characterizing pediatric preclinical models used for testing new agents. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17154184     DOI: 10.1002/pbc.21099

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  33 in total

1.  Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.

Authors:  Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

2.  A set of imprinted genes required for normal body growth also promotes growth of rhabdomyosarcoma cells.

Authors:  Geoffrey Rezvani; Julian C K Lui; Kevin M Barnes; Jeffrey Baron
Journal:  Pediatr Res       Date:  2012-01       Impact factor: 3.756

3.  A bioinformatics analysis of the cell line nomenclature.

Authors:  Sirarat Sarntivijai; Alexander S Ade; Brian D Athey; David J States
Journal:  Bioinformatics       Date:  2008-10-10       Impact factor: 6.937

4.  Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy.

Authors:  Shashank R Sirsi; Molly L Flexman; Fotois Vlachos; Jianzhong Huang; Sonia L Hernandez; Hyun Keol Kim; Tessa B Johung; Jeffrey W Gander; Ari R Reichstein; Brooke S Lampl; Antai Wang; Andreas H Hielscher; Jessica J Kandel; Darrell J Yamashiro; Mark A Borden
Journal:  Ultrasound Med Biol       Date:  2012-03-16       Impact factor: 2.998

5.  EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.

Authors:  Christopher H Evans; Fangjun Liu; Ryan M Porter; Regina P O'Sullivan; Taha Merghoub; Elaine P Lunsford; Kyle Robichaud; Frans Van Valen; Stephen L Lessnick; Mark C Gebhardt; James W Wells
Journal:  Clin Cancer Res       Date:  2012-08-09       Impact factor: 12.531

6.  Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Authors:  Duck Cho; David R Shook; Noriko Shimasaki; Yu-Hsiang Chang; Hiroyuki Fujisaki; Dario Campana
Journal:  Clin Cancer Res       Date:  2010-06-11       Impact factor: 12.531

7.  Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.

Authors:  Patrick J Grohar; Girma M Woldemichael; Laurie B Griffin; Arnulfo Mendoza; Qing-Rong Chen; Choh Yeung; Duane G Currier; Sean Davis; Chand Khanna; Javed Khan; James B McMahon; Lee J Helman
Journal:  J Natl Cancer Inst       Date:  2011-06-08       Impact factor: 13.506

Review 8.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

9.  FAK inhibition abrogates the malignant phenotype in aggressive pediatric renal tumors.

Authors:  Michael L Megison; Lauren A Gillory; Jerry E Stewart; Hugh C Nabers; Elizabeth Mrozcek-Musulman; Elizabeth A Beierle
Journal:  Mol Cancer Res       Date:  2014-01-24       Impact factor: 5.852

10.  Molecular characterization of the pediatric preclinical testing panel.

Authors:  Geoffrey Neale; Xiaoping Su; Christopher L Morton; Doris Phelps; Richard Gorlick; Richard B Lock; C Patrick Reynolds; John M Maris; Henry S Friedman; Jeffrey Dome; Joseph Khoury; Timothy J Triche; Robert C Seeger; Richard Gilbertson; Javed Khan; Malcolm A Smith; Peter J Houghton
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.